{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:06:57Z","timestamp":1788286017590,"version":"build-2803163510"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Disseminated superficial actinic porokeratosis (DSAP) is an inherited or sporadic disorder of keratinization associated with germline variations. There is no effective standard of care therapy for DSAP, but treatment with topical lovastatin combined with cholesterol cream has shown promise.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate and compare the safety and efficacy of topical lovastatin 2% plus cholesterol 2% cream (lovastatin-cholesterol) and topical lovastatin 2% cream (lovastatin) alone in adults diagnosed with DSAP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This patient- and assessor-blinded, randomized clinical trial was conducted at the Medical University of South Carolina between August 3, 2020, and April 28, 2021. Nonpregnant adults with a previous clinical or histological diagnosis of DSAP were eligible. Data were blindly analyzed after study completion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Participants were randomized to once- or twice-daily application of either lovastatin-cholesterol cream (n\u2009=\u200917) or lovastatin cream (n\u2009=\u200914) to symptomatic regions for 12 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary efficacy measure was the effect of the treatment on DSAP at the end of treatment (12 weeks) as measured by the DSAP General Assessment Severity Index (DSAP-GASI; scored from 0-4, with 0 indicating clear and 4 indicating severe). Treatment efficacy was based on investigator-standardized photographs provided by the participants because of the need for evaluation via telehealth during the COVID-19 pandemic. Secondary efficacy measures included patient-reported outcomes, application frequency, and adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 87 participants screened, 32 were enrolled. One participant randomized to receive lovastatin-cholesterol did not receive the intervention, leaving 17 participants (mean [range] age, 59.2 [40-83] years; 13 females [76.5%]; all White) allocated to receive lovastatin-cholesterol treatment and 14 participants (13 female [92.9%]; mean (range) age, 53.7 [33-71] years; all White) to receive lovastatin treatment. Twelve participants in each treatment group qualified for the analysis. Disease severity decreased from week 1 to week 12 by 50.0% (from 3.08 [95% CI, 2.57-3.60] to 1.54 (95% CI, 1.04-2.05] points on the DSAP-GASI; <jats:italic>P <\/jats:italic>&amp;amp;lt; .001) in the lovastatin-cholesterol group and 51.4% (from 2.92 [95% CI, 2.40-3.43] to 1.50 [95% CI, 0.99-2.01] points; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) in the lovastatin group. There was no significant difference between the treatment groups according to application frequency at the end of 12 weeks. Adverse events reported included myalgia (n\u2009=\u20092), elevation in the creatine kinase level (n\u2009=\u20091), application discomfort (n\u2009=\u20094), and rash (n\u2009=\u20091). No serious AEs occurred, and all participants with an AE were able to complete the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This randomized clinical trial found improvements in DSAP severity in both treatment groups, without serious AEs, indicating a limited benefit with the addition of cholesterol. These results suggest that lovastatin cream may be a new primary treatment option for patients diagnosed with DSAP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359823\">NCT04359823<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.0205","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:16:24Z","timestamp":1679498184000},"page":"488","source":"Crossref","is-referenced-by-count":44,"title":["Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic Porokeratosis"],"prefix":"10.1001","volume":"159","author":[{"given":"Gabriella","family":"Santa Lucia","sequence":"first","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almeera","family":"Lateef","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Drohan","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew J.","family":"Gregoski","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Barton","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi230005r1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ijd.1973.12.issue-3","article-title":"Disseminated superficial actinic porokeratosis (DSAP).","volume":"12","author":"Chernosky","year":"1973","journal-title":"Int J Dermatol"},{"key":"doi230005r2","author":"Shakhbazova","year":"2020"},{"key":"doi230005r3","author":"Novice","year":"2021"},{"key":"doi230005r4","doi-asserted-by":"publisher","first-page":"24226","DOI":"10.1038\/srep24226","article-title":"Loss-of-function mutation in PMVK causes autosomal dominant disseminated superficial porokeratosis.","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"doi230005r5","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.jid.2019.07.723","article-title":"Second-hit somatic mutations in mevalonate pathway genes underlie porokeratosis.","volume":"139","author":"Atzmony","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi230005r6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2019.08.043","article-title":"Topical cholesterol\/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy.","volume":"82","author":"Atzmony","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"doi230005r7","article-title":".","author":"Tomsitz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi230005r8","author":"Ugwu","year":"2020"},{"key":"doi230005r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.043"},{"key":"doi230005r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.08.017"},{"key":"doi230005r11","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002089"},{"key":"doi230005r12","doi-asserted-by":"publisher","DOI":"10.1111\/ced.1994.19.issue-3"},{"issue":"2","key":"doi230005r13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.2019.181.issue-2","article-title":"Novel mutations in mevalonate kinase cause disseminated superficial actinic porokeratosis.","volume":"181","author":"Zhu","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230005r14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v34.1","article-title":"Refractory disseminated superficial actinic porokeratosis effectively treated with cholesterol\/lovastatin cream: a case report.","volume":"34","author":"Maronese","year":"2021","journal-title":"Dermatol Ther"},{"issue":"1","key":"doi230005r15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ajd.v62.1","article-title":"Effective treatment of disseminated superficial actinic porokeratosis using a novel topical cholesterol\/simvastatin combination cream.","volume":"62","author":"Jerjen","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"3","key":"doi230005r16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/ajd.v62.3","article-title":"Topical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: an open-label, split-body clinical trial.","volume":"62","author":"Byth","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"3","key":"doi230005r17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/archdermatol.2010.4","article-title":"Prevalence of a history of skin cancer in 2007: results of an incidence-based model.","volume":"146","author":"Stern","year":"2010","journal-title":"Arch Dermatol"},{"issue":"2","key":"doi230005r18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5021\/ad.2018.30.2.211","article-title":"Disseminated superficial actinic porokeratosis in a patient with psoriasis, after long-term narrowband ultraviolet B phototherapy.","volume":"30","author":"Sim","year":"2018","journal-title":"Ann Dermatol"},{"key":"doi230005r19","doi-asserted-by":"publisher","author":"Lucia","year":"2022","DOI":"10.1016\/j.jaad.2022.02.032"},{"key":"doi230005r20","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2710"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2802464\/jamadermatology_santa_lucia_2023_oi_230005_1684162775.03833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T15:08:10Z","timestamp":1684336090000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2802464"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.0205","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}